Device closure of muscular ventricular septal defects using the Amplatzer muscular ventricular septal defect occluder: Immediate and mid-term results of a U.S. registry

TL;DR: The role transcatheter therapy plays in the treatment of each major type of congenital heart lesion is considered and the clinical ramifications of the interventions rather than their technical aspects are considered.

TL;DR: This work describes the first case of iatrogenic membranous VSD in the setting of mitral valve replacement and tricuspid valve repair, using the newly approved Amplatzer Duct Occluder II Device from an entirely retrograde approach.

TL;DR: It is reported that the percutaneous closure of a complex traumatic ventricular septal defect resulting from a stab wound to the anterior chest with diminished cardiac function is reported, and the patient presented with heart failure 3 months after the initial trauma.

TL;DR: In this article, a 13-year-old boy was stabbed with a pair of scissors through his heart and a significant residual left-to-right shunt was found to have residual VSD.

TL;DR: It is suggested that ongoing spontaneous resolution of residual shunting occurs after device insertion, and factors related to the defect or device could not predict eventual resolution of remnant shunting.

TL;DR: Perventricular closure of multiple muscular ventricular septal defects is safe and effective and could become the treatment of choice for any infant with muscular Ventricle free wall defects or any child with muscular ventricle sePTal defect and associated cardiac defects.

TL;DR: This encouraging initial clinical success indicates that the AVSDO is a promising device for transcatheter closure of MVSDs in children, and further clinical trials and longer follow-up are needed before the widespread use of this technique can be recommended.

TL;DR: The Amplatzer MVSD occluder is a safe and effective device for closure of MVSDs up to 12 mm in diameter and further clinical trials with this device are underway.